XcelLabs to empower accountants to think AI-first
The platform provides a comprehensive training and technology solution to help accountants develop fluency in AI and strategic thinking.
Central to this offering is XcelLabs Academy, which features online courses covering essential topics such as AI fundamentals, advisory skills, leadership, and practice management.
Utilising Navi AI technology, XcelLabs converts unstructured data from communications into actionable insights.
This innovative tool adapts to the unique emotions and needs of each user, enhancing the overall experience for accounting professionals.
The platform aims to instil an AI-first mindset in teams at larger firms while leveraging Navi. This includes ongoing coaching to refine conversations and advisory actions, ultimately empowering professionals to excel in their roles.
Currently in beta testing, these solutions are designed to help accountants achieve 'exceptional' performance.
XcelLabs sets itself apart from traditional tech platforms by integrating high-impact strategy with practical AI tools focused on upskilling individuals rather than merely automating tasks.
By pushing boundaries and leveraging AI for various business challenges, XcelLabs envisions the rise of AI-X(SM) firms that utilise AI to drive 'excellence'.
This initiative underscores the importance of maintaining a human-centric approach within the evolving accounting profession. PICPA CEO Jennifer Cryder said: 'AI is transforming how CPAs work and XcelLabs is focused on helping the profession evolve with it.
'At PICPA, we're proud to support a mission that aligns so closely with ours: empowering firms to use AI not just for efficiency, but to drive growth, value and long-term relevance.'
"XcelLabs to empower accountants to think AI-first" was originally created and published by The Accountant, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Microsoft Slashes 9,000 Jobs While Mark Zuckerberg's Meta Poaches $20 Million Worth Of AI Talent From OpenAI: Investor Warns Of 'Jealousy, Envy, And Helplessness' Among Tech Workers In Silicon Valley
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Microsoft Corp. (NASDAQ:MSFT) cut 9,000 jobs in its second 2025 layoff round while Meta Platforms Inc. (NASDAQ:META) and OpenAI ignite a talent war with compensation packages reaching $20 million annually, creating stark contrasts in Silicon Valley's artificial intelligence landscape. What Happened: The layoffs affect less than 4% of Microsoft's workforce across diverse teams and regions as the company maintains cost controls while investing $80 billion in AI data centers this fiscal year. Microsoft's gaming division, including Candy Crush parent King, eliminated 200 positions, marking the company's continued workforce reduction following 6,000 cuts in May. Don't Miss: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — Now Raising at $3/Share Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. Meanwhile, Meta's aggressive talent acquisition has sparked unprecedented compensation inflation. Deedy Das, an AI investor at Menlo Ventures, told Business Insider that three machine-learning engineers at OpenAI and Anthropic received offers between $8 million and $20 million annually from Meta. 'There's a ton of ripple effects I'm hearing in the Valley,' Das said, describing widespread 'jealousy, envy, and helplessness' among tech workers not receiving such packages. The bidding war intensified after Meta recruited Scale CEO Alexandr Wang in a $14.3 billion deal and poached six star researchers from OpenAI for its new Meta Superintelligence Labs. OpenAI CEO Sam Altman claimed Meta offered $100 million signing bonuses, though Meta CTO Andrew Bosworth dismissed these claims as dishonest during a company meeting. Why It Matters: Roy Bahat of Bloomberg Beta noted the talent shortage drives extreme valuations, with only approximately 2,000 researchers capable of building foundational AI models globally. 'In my 20 years in tech, I have never seen as clearly defined a market for extraordinary talent,' Bahat said. The competition extends to universities, where companies pressure Ph.D. interns to abandon studies. 'They're pressuring them to drop out of school,' said Bill Aulet of MIT's Martin Trust Center for Entrepreneurship. Companies argue AI advances are happening so rapidly that graduation delays could cost career-defining opportunities. Microsoft's third quarter revenue of $70.07 billion, up 13% year-over-year, and Azure's 33% growth demonstrate continued AI demand despite workforce reductions. Read Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's how you can earn passive income with just $100. Photo courtesy: Tada Images / This article Microsoft Slashes 9,000 Jobs While Mark Zuckerberg's Meta Poaches $20 Million Worth Of AI Talent From OpenAI: Investor Warns Of 'Jealousy, Envy, And Helplessness' Among Tech Workers In Silicon Valley originally appeared on
Yahoo
2 hours ago
- Yahoo
Jim Cramer on Palantir: 'I Say it Can be Bought'
Palantir Technologies Inc. (NASDAQ:PLTR) is one of the 25 stocks Jim Cramer recently shared insights on. Cramer highlighted his past predictions of the company stock going to $200 and said that he's 'sticking by that.' He commented: 'But what do we do with the very different set of winners for the first half? I want you to consider the GE Vernovas and the Howmets and the Palantirs, the stocks that are likely to finish the year dramatically higher from these exalted levels. What do you do with the stocks that have been on a run nonstop for 26 weeks, though? I think you send them on one of those two-week vacations like that Southeast Asia, Cape Town, maybe New Zealand. You pay no attention to them. Let them have a good time. Just take them off your screen, come back to them when the rotations run its course. A software engineer manipulating a vast network of code on virtual monitors. Palantir (NASDAQ:PLTR) develops software platforms that enable data integration, analysis, and decision-making for intelligence, defense, and commercial applications. The company provides tools like Gotham, Foundry, Apollo, and its AI platform to transform complex data into actionable insights. While we acknowledge the potential of PLTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Lunit partners with Microsoft to develop AI cancer diagnostic tools
South Korean AI company Lunit is collaborating with Microsoft to help bring its AI-powered diagnostics for cancer detection into clinical practice. According to Lunit, the partnership aligns with its vision to create AI tools that fit smoothly into everyday clinical care. The collaboration will involve Lunit and Microsoft's development of a tool for customising AI models that will be embedded into Microsoft's Azure cloud platform, thereby allowing Lunit users to customise their AI models using site-specific clinical data. Lunit adds that the approach will mitigate cross-site model performance variability, which it views as a key hurdle in the deployment of AI diagnostics in real-world clinical settings. The developer also plans to use Microsoft's agentic AI frameworks, which are designed to support intelligent task automation, to develop workflow automation tools. According to Lunit, these solutions will simplify clinical decision-making and improve operational efficiency for its AI cancer diagnostic tools. Lunit's AI tools include the SCOPE HER2 algorithm for human epidermal growth factor receptor 2 (HER2) biomarker evaluation in metastatic colorectal cancer (mCRC) patients undergoing HER2-targeted therapy, and INSIGHT DBT for identifying breast cancer in mammogram images. Lunit CEO Brandon Suh commented: 'Our collaboration with Microsoft enables us to bring our AI to more providers through trusted platforms like Microsoft Azure, helping us expand access in the US and beyond.' According to GlobalData analysis, the use of AI across healthcare is rapidly advancing, with the market projected to reach a valuation of around $19bn by 2027. Radiology has emerged as one of the most common areas in which AI is being applied – chiefly as a means to drive efficiencies and glean insights that humans evaluating radiologic images could miss. Naveen Valluri, general manager of health and life sciences data and AI at Microsoft, commented: 'With Microsoft Azure, we are shaping an ecosystem that supports partners like Lunit in delivering scalable AI innovations. 'By combining our infrastructure with clinical-grade AI developed in close collaboration with leaders like Lunit, we're accelerating the development of integrated solutions for radiology and beyond.' "Lunit partners with Microsoft to develop AI cancer diagnostic tools" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
